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HIV-1 Tat is able to form a ternary complex with P/CAF and p300 and increase the affinity for CDK9/P-TEFb CTD kinase
complex. Our previous study demonstrated that Tat binds to p300/CBP in the minimal HAT domain (aa 1253–1790) and that
the interaction results in a change of conformation on p300/CBP. Here, we show that the Tat–p300 interaction increases the
HAT activity of p300 on histone H4 that is associated with nucleosomal DNA and not with free histones. Nucleosomal histone
H4 was acetylated on lysines 8, 12, and 16. Acetylation of H4 was inhibited by Lys-coenzyme A (CoA), a selective inhibitor
of p300 acetyltransferase activity. Unexpectedly, we also found that Tat could autoacetylate itself, which was specific to lysine
residues 41 and 71. Peptides lacking these two lysines could not enhance the HAT activity of p300. Comparison of the
sequences of Tat with other HIV-1 clades and HAT containing transcription factors indicated sequence identity in the
acetyl-CoA binding motif A, KGXG. Furthermore, when utilizing an in vitro transcription assay, as well as a Tat mutant virus,
we found that ectopic expression of only wild-type Tat in the presence of p300, and not a lysine 41 Tat mutant, could activate
HIV-1 chromatin DNA, as evidenced by the absence of HIV-1 virion antigen. Therefore, transcription of integrated viral DNA
in vivo requires the HAT activity of coactivators that are modulated by Tat to derepress the HIV-1 chromatin structure and
aid in activated transcription. © 2001 Academic PressINTRODUCTION
The HIV-1 Tat is required for viral replication and is a
potent stimulator of viral transcription. Gene expression
from the viral long terminal repeat (LTR) is several hun-
dredfold higher in the presence of Tat. The ability of Tat
to regulate viral transcription is related to its ability to
bind to TAR (trans-activation responsive) and interact
with cdk9/cyclinT1 complex, resulting in a more efficient
elongation of the RNA Pol II complex (O’Keeffe et al.,
2000; Romano et al., 1999; Napolitano et al., 1999; Isel
and Karn, 1999; Bieniasz et al., 1999; Ramanathan et al.,
1999; Ivanov et al., 1999; Chen et al., 1999; Wimmer et al.,
1999; Garriga et al., 1998; Garber et al., 1998; Fujinaga et
al., 1998; Wei et al., 1998). For optimal transactivation of
HIV-1 gene expression and high viral load, Tat also
requires specific upstream transcription factors, includ-
ing Sp1 (Jeang et al., 1993), TATA binding protein (Ka-
shanchi et al., 1994; Veschambre et al., 1995; Majello et
al., 1998), Tat-associated kinase (TAK) (Herrmann and
Rice, 1995; Yang et al., 1996), TFIIH (Garcia-Martinez et
al., 1997; Parada and Roeder, 1996), Tip (Jeang et al.,
1993; Henderson et al., 1999), and RNA polymerase II
(Cujec et al., 1997; Mavankal et al., 1996).1 To whom correspondence and reprint requests should be ad-
ressed. Fax: (202) 994-1780. E-mail: bcmfxk@gwumc.edu.
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312HIV-1 proviral DNA is integrated into the host cell
chromosomes and packaged into chromatin. The LTR,
which acts as a very strong promoter when analyzed as
naked DNA in vitro, is silent when integrated into the
cellular host genome in the absence of any stimuli (Ver-
din, 1991; Van Lint et al., 1996; Marzio et al., 1998; Ben-
kirane et al., 1998). Therefore, physiological mechanisms
for proviral transcription account for the activation of
chromatin-associated viral genomes.
It is known that the four histones, which comprise the
nucleosome core (H2A, H2B, H3, and H4), participate in
the transcriptional regulation of numerous genes (Owen-
Hughes and Workman, 1994). The core histones undergo
several posttranslational modifications including phos-
phorylation, methylation, ADP-ribosylation, ubiquitina-
tion, and/or acetylation. The reversible acetylation of the
E-amino groups of the lysine residues present in the
amino-terminal domain of the core histones is the mod-
ification most strongly linked with transcriptional activity.
Two classes of enzymes for histone acetylation have
been identified. Cytoplasmic type-B histone acetyltrans-
ferases (HATs) are thought to acetylate free histones that
subsequently are assembled into chromatin, while nu-
clear type-A histone acetytransferases are thought to
carry out transcription-related acetylation of chromo-
somal histones (Roth and Allis, 1996; Strahl and Allis,
2000). Many type-A HATs have been identified from the
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313ENHANCEMENT OF p300 HAT ACTIVITY BY HIV-1 Tattranscriptional regulatory proteins, such as GCN5, CBP/
p300, P/CAF (human homologue to GCN5), TAFII250,
Tip60, and nuclear hormone receptor ACTR (Sterner and
Berger, 2000).
CBP and p300 are two highly homologous proteins
that behave as transcriptional coactivators and cooper-
ate with a number of sequence-specific transcription
factors. It has been suggested that CBP/p300 acts as a
central integrator of transcriptional signals from various
signal transduction pathways (Kamei et al., 1996). In
addition, CBP/p300 has intrinsic HAT activity and is able
to cooperate with transcription factors through chromatin
remodeling or the modification of histone and nonhis-
tone proteins. The HAT activity of p300/CBP is also reg-
ulated by other factors such as viral proteins. For in-
stance, it has been reported that the HAT activity of
CBP/p300 is stimulated by interaction with E1A or phos-
phorylation by cdk2/cyclin E complex (Ait-Si-Ali et al.,
998).
Many lines of evidence indicate a relationship be-
ween histone acetylation and gene activity. For example
n Drosophila, equalization of transcription from the sex
hromosomes is achieved by a twofold upregulation of
ranscription from the male X chromosome that is asso-
iated with acetylation of H4 at lysine 16. Chromatin
mmunoprecipitations of the activated gene with the an-
ibodies against the specific acetylation sites in H3 and
4 reveal an enrichment of transcribed sequences.
oreover, recent evidence suggests that acetylation of
pecific lysine residues in the amino-termini of the core
istones by different HAT enzymes plays a fundamental
ole in transcriptional regulation (Strahl and Allis, 2000).
or instance, transcription-linked acetylation, catalyzed
y the GCN5 family of HATs, shows a preference for
ysine 14 of H3 and 8 of H4 in vitro, although an expanded
et of lysine residues is likely to be used in vivo. P/CAF
rimarily acetylates lysine 14 of H3 and less efficiently
cetylates lysine 8 of H4. CBP/p300 acetylates all his-
ones, but preferentially acetylates lysines 14 and 18 of
3 and lysines 5 and 8 of H4 with nucleosomal sub-
trates (Schiltz et al., 1999). These distinct patterns of
cetylation by the CBP/p300 and P/CAF may contribute
o their differential roles in transcriptional regulation.
ollectively, these data support the theory that acetyla-
ion on the N-termini of core histones is important for
ranscriptional regulation.
Recently, several reports have provided evidence for
he existence of an intracellular multiprotein complex
hat contains Tat, CBP/p300, and P/CAF (Kiernan et al.,
999; Hottiger et al., 1998). HIV-1 Tat is able to form a
ernary complex with P/CAF and p300 to stimulate the
bility of Tat to activate LTR-dependent transcription.
oreover, the formation of such a complex containing
at and p300 targets these proteins to the viral promoter.
he histone acetyltransferase activity of CBP/p300 and
/CAF is preferentially required for Tat function (Kiernan
T
tt al., 1999). However, Tat is also capable of forming
omplexes with a component of TFIID, the TAFII250
Weissman et al., 1998) and Tip60 (Creaven et al., 1999).
In these cases, Tat-TAFII250 and Tat-Tip60 do not affect
the transcription from the LTR, but interfere with the
transcriptional activity of these cellular genes. It is pos-
tulated that different targets of HATs by Tat have different
consequences. The interaction of Tat with CBP/p300 and
P/CAF stimulates its ability to transactivate LTR-depen-
dent transcription, while TAFII250 or Tat-Tip60 interaction
ontrols the transcription of cellular genes (Creaven et
l., 1999).
In addition to histone acetylation, some HATs are
nown to modify certain nonhistone transcription-related
roteins, such as p53, E2F, and high-mobility-group chro-
atin proteins. Similar to certain cellular transcription
actors, Tat is also acetylated by CBP/p300 and P/CAF
Kiernan et al., 1999; Ott et al., 1999). P/CAF-acetylated
at was found to have an increased affinity for CDK9/P-
EFb CTD kinase complex, suggesting that this acetyla-
ion event enhances transcriptional elongation by the
yperphosphorylation of the RNA polymerase II CTD.
Our previous work indicated that acetylation of Tat by
BP/p300 decreased Tat’s ability to bind to the TAR RNA
lement and allowed better binding to core histones on
n assembled chromatin template (Deng et al., 2000). Tat
inds to the minimal HAT domain (aa 1253–1790) of
BP/p300 and the interaction results in a change of
onformation for CBP/p300. In this study, we asked
hether Tat affects the intrinsic HAT activity of p300. We
ound that Tat–p300 interaction increases the HAT activ-
ty of p300 on histone H4 associated with nucleosomal
NA. The acetylation can specifically be blocked by a
ynthetic inhibitor of p300 acetyltransferase activity,
amely, Lys–coenzyme A (CoA). Interestingly, we also
ound that Tat autoacetylates itself on lysines 41 and 71.
at alone cannot acetylate core histones, but enhances
300 HAT activity through its autoacetylation. Further-
ore, using in vitro transcription assays, we found that
at–p300 interaction increases the transcription from an
n vitro assembled whole HIV-1 viral or nucleosomal LTR
NA. Taken together, these observations suggest a pos-
ible mechanism by which Tat and the HAT activity of
BP/p300 play a critical role in the transcriptional acti-
ation of the integrated HIV-1 provirus.
RESULTS
utoacetylation of HIV-1 Tat
We have previously shown that CBP/p300 was able to
cetylate HIV-1 Tat at positions 50 and 51 and that the
cetylation was critical for transcription of integrated
IV-1 chromatin DNA and not transfected unorganized
NA (Deng et al., 2000). Upon close examination of the
at protein in acetylation experiments, we recently found
hat Tat was able to autoacetylate itself, albeit less effi-
a
H
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314 DENG ET AL.ciently, in the absence of exogenous CBP/p300 HAT
domain. The results of such an experiment are shown in
Fig. 1A, where Tat was acetylated efficiently by GST–HAT
(lane 1, 126,508 cpm), as well as autoacetylation of the
wild-type Tat in absence of the p300 HAT domain (lane 5,
18,308 cpm). To determine which region of Tat was re-
quired for autoacetylation, we used a series of Tat syn-
thesized peptides in an in vitro acetylation reaction. The
HAT acetylation reaction consisted of either substrate
Tat proteins (400 ng) or Tat peptides (200 ng) and a
mixture of histones H2A, H2B, H3, and H4 (1 mg total)
FIG. 1. Autoacetylation of HIV-1 Tat. (A) The core histones (H2A, H2B
GST–HAT and [14C]acetyl-CoA. The acetylated products were resolved
Band intensities were quantitated using Molecular Dynamics software
autoacetylation of the purified wild-type Tat in the absence of GST–HAT
Tat protein and various synthesized Tat peptides. The purified Tat (1–86)
n the presence or absence of GST–HAT. The acetylated products were
elative radioactivity of autoacetylated Tat peptides with and without Glone (“Autoacetylation”) or in the presence of GST–p300
AT (2 ml, 1 mg/ml, “1 GST–HAT”), in acetylation bufferwith [14C]acetyl-Coenzyme A (1 ml). All reactions were
incubated at 37°C for 60 min and resolved on a 4–20% or
15% SDS/PAGE, dried, and exposed to a PhosphorIm-
ager cassette. As seen in Fig. 1B, the minimum Tat
domain that was able to autocetylate itself efficiently was
the Tat 36–72 peptide. Other control peptides that were
missing lysines 41 or 71 were inefficient in autoacetyla-
tion reactions (peptides 38–70 and 42–72), and another
control peptide, 42–70, was completely inactive in auto-
acetylation experiments. Similar results were obtained
with a synthetic Tat protein (1–72), where mutation of K41
nd H4) and purified Tat protein (1–86) were incubated with or without
–20% SDS/PAGE, dried, and exposed to a PhosphorImager cassette.
as efficiently acetylated by GST–HAT (lane 1, 126,508 cpm), as well as
, 18,308 cpm). (B) Summary of the autoacetylation results using purified
–72) mutant proteins and peptides were incubated with [14C]acetyl-CoA
ated on a SDS/PAGE, exposed, and counted as mentioned above. The
T is shown in the right-hand columns., H3, a
on a 4
. Tat w
(lane 5
and (1and K71 abolished the autoacetylation. It is important to
note that all of the Tat peptides and proteins tested
s that
-1 clad
315ENHANCEMENT OF p300 HAT ACTIVITY BY HIV-1 Tatcontained lysines 50 and 51, which were efficiently acety-
lated by the p300 HAT domain (Fig. 1B, left column). To
FIG. 1. Continued. (C) MALDI-TOF mass spectrometry of peptide Ta
(bottom). Ac represents the number of acetyl groups added to the Tat pe
including the GCN5-related histone acetyltransferase family member
Alignment of various HIV-1 Tat consensus sequences from known HIVfurther test whether autoacetylation could occur in vitro,
we performed an autoacetylation assay with Tat (36–72)peptide along with cold acetyl-CoA and subjected the
peptides to matrix-assisted laser desorption-time of flight
2) (top) and autoacetylated Tat (36–72) (in the absence of GST–HAT)
D) Sequence alignment of various transcription and coactivator factors
contain the conserved acetyl-CoA binding motif A sequence KGXG.
es and their conservation in the KGXG sequence.t (36–7
ptide. ((MALDI-TOF) mass spectrometry analysis. The results of
such an experiment are shown in Fig. 1C, where the
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316 DENG ET AL.acetylated Tat showed two predominant populations, a
major peak of the acetylated peptide at lysine 41 or 71 (1
Ac) and the other diacetylated peak showing both acety-
lated lysines (2 Ac, Bottom). Interestingly, the comparison
of the sequences of Tat (34–56) with other known HAT
containing transcription factors from human to yeast
showed sequence identity in motif A, KGXG, which is the
binding site to acetyl-CoA. Similar sites were also 100%
conserved in all of the HIV-1 consensus clades se-
quenced to date (Fig. 1D). Finally, to determine whether
the KGLG present in Tat sequence was essential for
autoacetylation, we synthesized a wild-type and a Tat
(1–72) deletion mutant. Both proteins were purified using
reverse-phase HPLC following synthesis, and quantified
by BCA assay as well by running a small aliquot on
SDS/PAGE for quality control. The results in Fig. 1E show
that when the KGLG sequence was deleted, autoacety-
lation was also abolished, and as expected the protein
still served as a good substrate for GST–HAT. Impor-
tantly, when assaying for in vivo function (Kashanchi et
al., 1992), only the wild-type protein could activate tran-
scription in a transient transfection experiment (Fig. 1F),
indicating that the KGLG sequence was essential for Tat
activated transcription. A Western blot from the trans-
FIG. 1. Continued. (E) Similar to B, where 1 mg of each protein was
of CEM cells with HIV-1 LTR-CAT (3 mg) in the presence or absence of
urified Tat (1–72) protein, and lanes 3–5 contained DNA plus 1, 3, a
electroporated with both the DNA and the protein at the same time, infected CEM cells showed equal Tat protein recovery,
indicating that both the mutant and the wild-type Tat
w
sproteins were able to translocate into the nucleus (data
not shown).
Tat enhances the nucleosomal H4 acetylation by
p300
It has previously been shown that p300 binds to Tat at
both core and basic residues (Marzio et al., 1998; Ben-
kirane et al., 1998; Hottiger et al., 1998). Our previous
work indicated that Tat interacts with multiple p300 do-
mains, with the strongest binding to the minimal HAT
domain (aa 1253–1790) (Deng et al., in press). To assess
whether Tat may affect the intrinsic HAT activity of p300
in vitro, we used free core histones as substrates in a
HAT assay. Following the reaction, the histones were
resolved on a 4–20% SDS/PAGE, and the 14C-labeled
roducts were detected after autoradiography. Bacteri-
lly expressed GST–p300 (HAT domain) could efficiently
cetylate all core histones (H2A, H2B, H3, and H4) and
at alone did not acetylate free histones (Fig. 2A, lanes 1
nd 7). However, a more interesting pattern emerged
rom the nucleosomal assembled DNA substrates. Using
ucleosomal histones assembled with full-length HIV-1
NA (pDH125), acetylation of only H2A and H2B histones
r either autoacetylation or acetylation with GST–HAT. (F) Transfection
tein. Lane 1 contained no Tat, lane 2 contained DNA plus 1 mg of the
g of the mutant Tat (1–72) protein in the transfection mix. Cells were
d at 37°C overnight, and lysed for CAT assay the next day.used fo
Tat proas observed (lane 2). Interestingly, when using salmon
perm nucleosomal DNA as a substrate, GST–p300 (HAT
a
2
n
317ENHANCEMENT OF p300 HAT ACTIVITY BY HIV-1 Tatdomain) exhibited no acetylation on this complex (data
not shown), indicating that the choice of DNA for chro-
matin assembly in vitro makes a significant difference in
the outcome of the acetylation results. Possible explana-
tions for the observed difference could be at the level of
DNA structure, supercoiled plasmid DNA vs random oli-
FIG. 2. Tat-enhanced acetylation of histone H4 by the p300 HAT dom
acetylated by GST–HAT in the presence or absence of Tat. The 14C-labe
to a PhosphorImager cassette. Substrates for the HAT assay were as fo
with a mono- and T-tropic HIV-1 whole-genome plasmid DNA (pDH125).
mixed with or without histones and sequentially diluted from 1 to 0.1 M
with ethidium bromide for quality control prior to the experiment (data
Tat, indicating that Tat alone cannot acetylate free histones. (B) Nucle
GST–HAT in the presence of wild-type Tat (36–72) (lanes 1 and 3), Tat
a 4–20% SDS/PAGE, stained first with Coomassie blue (bottom) and then
on inhibition of H4 acetylation. Free core histones (lanes 3 and 4) wer
cetylation of all histones were observed. At the same concentration,
) by Lys-CoA. Histone H4 was reduced 8-fold (from 2368 to 291 c
ucleosomal and naked DNA. Aliquots of the assembled pDH125 chro
15 min (lane 2), 45 min (lane 3), and 65 min (lane 4). As control, aliquot
the same conditions as the assembled pDH125 chromatin DNA. The d
with ethidium bromide.gomers of A, B, and Z forms present in salmon sperm
DNA, and possible requirement of linker histones, suchas histone H1, H5, or HMG proteins, for higher order
chromatin structure in long linear DNA.
Interestingly, when we incubated GST–p300 (HAT) with
HIV-1 nucleosomal histones in the presence of Tat, we
observed a high level of histone H4 acetylation (lane 3).
Tat by itself was not able to acetylate the HIV-1 nucleo-
) Free core histones and the assembled nucleosomal histones were
tylated products were separated on a 4–20% SDS/PAGE and exposed
ane 1, free core histones; lanes 2–5, assembled nucleosomal histones
ing nucleosomal assembly of the pDH125 plasmid DNA, samples were
alt buffer. Samples were separated on a 1% agarose gel and stained
wn). Lanes 6 and 7 represent controls in the presence or absence of
l histones assembled with pDH125 plasmid DNA were acetylated by
(lane 2), or Tat (36–72) mutant (lane 4). Reactions were separated on
nd exposed to a PhosphorImager cassette (top). (C) Effects of Lys-CoA
ated with GST–HAT and 5 mM Lys-CoA and a 10-fold reduction in the
as a complete nucleosomal inhibition of H4 acetylation (lanes 1 and
d Tat by 3-fold (from 44,759 to 14,881). (D) MNase digestion of the
NA (100 ml, ;5 mg DNA) were digested by micrococcal nuclease for
ked plasmid pDH125 DNA (lane 5, 6, and 7) were also digested under
DNAs were precipitated and run on a 1.2% agarose gel and stainedain. (A
led ace
llows: L
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318 DENG ET AL.p300 HAT activity on nucleosomal H4 to be associated
with the presence of the Tat peptide. To determine
whether autoacetylation of Tat was important for the
acetylation of nucleosomal H4, we incubated the nucleo-
somal HIV-1 DNA with wild-type Tat (36–72), Tat (42–70),
or Tat (36–72) double 41/71 mutant (K to A substitution),
along with GST–p300 HAT. The results of such an exper-
iment are shown in Fig. 2B, where p300 HAT along with
only wild type and not the 42–70 or double-lysine mutant
was able to acetylate nucleosomal H4. Finally, we uti-
lized the effect of a potent p300 inhibitor in vitro and
found that Lys-CoA, as expected (Lau et al., 2000), inhib-
ted the acetylation of free core histones by 10-fold (Fig.
C, lane 3 and 4). More importantly, at an IC50 of approx-
mately 5 mM, there was a complete nucleosomal inhi-
ition of the H4 acetylation (lanes 1 and 2), indicating that
he Tat-enhanced p300 acetylation activity can be inhib-
ted by HAT inhibitors. As a control we consistently per-
ormed the MNase assay on naked vs assembled DNA
rior to HAT assays to ensure chromatin assembly. As
an be seen in Fig. 2D assembled DNA is much more
esistant to MNase treatment than naked DNA. Finally
nd of particular interest, a P/CAF inhibitor, H3-CoA-20
Lau et al., 2000), inhibited full-length Tat autoacetylation
IC50 of 30 mM, ;70%) in a nucleosomal HAT assay and
he overall rate of acetylation of free Tat (36–72) showed
first-order rate constant at 20 mM acetyl-CoA, which is
about 1000- to 10,000-fold slower than p300 or P/CAF in
vitro (data not shown).
Increased acetylation of the H4 lysine residues in the
presence of p300 HAT and Tat
To address whether H4 lysine residues were acety-
lated in the presence of Tat, we utilized an immunopre-
cipitation assay with ChIP grade anti-acetyl-H4 antibod-
ies. The results of such an experiment are shown in Fig.
3A, where polyclonal antibodies against H4 were able to
pull down H4 from a chromatin assembled DNA (lane 2).
As expected the p300 HAT domain efficiently acetylated
the free histones as evident in the H4 immunoprecipi-
tates (lane 3). To address which H4 lysines on nucleo-
some DNA were acetylated by Tat–p300 interaction, we
used antibodies specific against lysine 5, 8, 12, and 16 in
immunoprecipitation (IP) reactions following the HAT as-
say. Antibodies used for IP were first evaluated on a
SDS/PAGE for quality and amounts (heavy and light
chains) prior to the immunoprecipitations. The immuno-
precipitated H4 was then resolved on a SDS/PAGE, and
the HAT activity was detected following autoradiography.
Figure 3B shows the histogram for the IP reaction, where
three antibodies were able to immunoprecipitate the
histone H4 off of the chromatin DNA, and lysines 8, 12,
and 16 were all acetylated to varying degrees. Interest-
ingly, lysine 16, which has previously been correlated
with increased transcription (Strahl and Allis, 2000), wasthe most acetylated residue in the presence of wild-type
Tat and not the double-mutant Tat.
Histone acetylation increases transcription of HIV-1
chromatin DNA in vitro
In vivo, acetylation of histone H4 at lysines 8 and 16
correlates well with increased transcriptional activity
(Strahl and Allis, 2000). The ability of Tat to enhance the
acetylation of nucleosome histone H4 allowed us to
directly test whether the Tat–p300 interaction would in-
FIG. 3. Increased acetylation of H4 lysines in the presence of p300–
HAT and Tat. (A) Nucleosomal histones assembled with pDH125 plas-
mid DNA were acetylated by GST–HAT in the presence (lane 2) or
absence (lane 1) of Tat. Samples were immunoprecipitated with ChIP
grade anti-acetyl-H4 antibodies. Immunoprecipitated 14C-labeled H4
ysines were separated on 4–20% SDS/PAGE, dried, and exposed. (B)
ucleosomal histones were immunoprecipitated with antibodies spe-
ific against lysine 5, 8, 12, and 16 following the HAT assay in the
resence of Tat (36–72) wild-type, Tat (36–72) mutant, or Tat (42–70).
he quality of all antibodies was determined by running a small amount
100 ng) on SDS/PAGE and staining for heavy and light chains prior to
mmunoprecipitations. Immunoprecipitates were separated on a 4–20%
DS–PAGE, dried, and exposed. Radioactive bands were counted us-
ng Molecular Dynamics software.crease the transcription from the chromatin LTR in vitro.
Nucleosomes were assembled on biotinylated HIV-1 LTR
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319ENHANCEMENT OF p300 HAT ACTIVITY BY HIV-1 TatDNA template first and then immobilized using strepta-
vidin agarose beads (Fig. 4A). The immobilized chroma-
tin LTR was washed in acetylation buffer and used as a
substrate for acetylation by p300 in the presence or in
the absence of Tat. Following the acetylation reaction,
the template was washed in transcription buffer and
used in an in vitro run-off transcription reaction. Assem-
ly of the nucleosome led to a tight repression of the HIV
TR transcription (Fig. 4B, lane 2), and not the nonnu-
leosomal DNA (lane 1). Addition of the wild-type Tat
36–72), and not the double-mutant, prior to the transcrip-
ion reaction increased the transcription from the chro-
atin template (lanes 3–5), presumably by its ability to
nhance the acetylation of nucleosomal H4. Addition of
at (36–72) wild-type, Tat mutant, or 42–70 peptides dur-
ng the transcription did not enhance the transcription of
ucleosomal DNA (data not shown). Finally, to assess
hether acetylation of histone H4 perturbed the nucleo-
ome, we performed pull-down experiments on pre- and
osttranscription templates. As shown in Fig. 4C, all
istones remained bound to DNA before and after in vitro
transcription reaction, indicating that acetylation of his-
tone H4 does not perturb the nucleosomal structure nor
does it aid in the removal of core histones from DNA
(lanes 3 and 4). Taken together, these observations in-
dicate that Tat with its association with the p300 HAT
domain acetylates histone H4, which aids in the tran-
scription of repressed chromatin.
Effect of the Tat lysine mutation on viral replication
We used HLM-1 cells to address whether the interac-
tion of Tat and p300 plays a role in the activation of
integrated proviral HIV-1 sequence in vivo. HLM-1 cells
were derived from HeLa-T41 cells containing an inte-
grated copy of the HIV-1 proviral genome with a Tat-
defective mutation (termination linker at the first AUG).
HLM-1 cells are negative for virus particle production,
but can be induced to express high levels of infectious
HIV-1 particles after transfection with Tat expressing
clones, stimulation with cytokines, such as TNF-a, or
eneral inducers, such as sodium butyrate. In order to
est whether the coactivator p300 plays a critical role in
he activation of integrated HIV-1, we transfected the
LM-1 cells with either the wild-type or the mutant Tat in
he presence or absence of p300. Supernatants were
ollected at days 3, 7, and 10 for p24 gag ELISA. The
esults of such an experiment are shown in Fig. 5A
here ectopic expression of p300 along with wild-type
at activated the viral production by three- to fourfold.
owever, the lysine 41 mutant of Tat either alone or in
ombination with p300 did not activate the latent virus.
imilar results were seen with increased titrations ofysine 41 mutant plasmid that were carried out to 90 days
data not shown). Taken together these data indicate that
i
Hhe Tat 41 lysine residue is important for the activation of
ntegrated HIV-1 promoter activity.
DISCUSSION
Virus infection or activation of infected cells results in
dramatic hyperacetylation of histones H3 and H4,
hich have been shown to localize to specific cellular
romoters (Parekh and Maniatis, 1999). By inference,
esults from a number of laboratories in the past few
ears have shown a dramatic increase in viral transcrip-
ion when HIV-1-infected cells or cells carrying stably
ntegrated HIV-1 LTR were treated with histone deacety-
ase inhibitors, such as n-butyrate (Laughlin et al., 1993,
995), TSA, or trapoxin (Van Lint et al., 1996). This is due
mainly to the fact that stably integrated HIV-1 provirus is
packaged into chromatin (Mirkovitch, 1997; El Kharroubi
et al., 1998), and two nucleosomes (called nuc-0 and
nuc-1) have been shown to be deposited onto the viral
DNA promoter at precise locations with respect to reg-
ulatory elements (Verdin, 1991; Verdin et al., 1993). It has
een shown that the binding of transcription factors p50
nd Sp1 leads to a reconfiguration of the chromatin
tructure in the proximal promoter region (Pazin et al.,
996) and that the LTR nucleosomal arrays containing
p1 and NF-kB1 produce regions of enhanced DNase I
ensitivity, specifically at the HIV-1 nucleosome (Steger
nd Workman, 1997). Therefore, a combination of Sp1
nd multiple distal enhancer binding proteins was re-
uired to derepress the HIV-1 transcription in chromatin
econstitution experiments (Sheridan et al., 1995).
Tat is also acetylated by CBP/p300 and P/CAF (Kier-
an et al., 1999; Ott et al., 1999), which increases the
affinity for the CDK9/P-TEFb CTD kinase complex. We
have previously shown that Tat binds to CBP/p300 in the
minimal HAT domain (aa 1253–1790) and the interaction
results in a change of conformation on CBP/p300 (Deng
et al., in press). Our current results indicate that the
Tat–p300 interaction increases the HAT activity of p300
on histone H4-associated nucleosomal DNA and not free
histones. Nucleosomal histone H4 was acetylated to
varying degrees on lysines 8, 12, and 16, which corre-
lates well with the increased transcriptional activity. This
is in contrast to p300’s specificity, where it can acetylate
preferentially at Lys 5 and Lys 8 (Sobel et al., 1994, 1995;
chiltz et al., 1999). Therefore, Tat’s ability to modulate
300 HAT activity and increase its acetylation profile may
xplain the increase in transcription observed in our in
itro run-off assay. A clear correlation between H4 acet-
lation and increased transcription has been demon-
trated on a number of promoters, including the Hsp26
ene and activator protein MOF (Vettese-Dadey et al.,
996; Imhof et al., 1997; Akhtar and Becker, 2000). This is
lso consistent with previously published reports wheren the absence of transcription (Marzio et al., 1998),
AT-associated complexes showed an increase in the
f
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320 DENG ET AL.FIG. 4. Histone acetylation increases the transcription of HIV-1 chromatin template in vitro. (A) The diagram depicts the experimental procedure
or obtaining biotin-labeled HIV-1 LTR, chromatin assembly, and pull-down with streptavidin beads followed by an in vitro transcription reaction. (B)
mmobilized chromatin HIV-1 LTR templates (1 mg) were acetylated in the presence of GST–HAT (lane 3–5, 7, and 8) or wild-type Tat (36–72) (lane 3,
100 ng; lane 4, 200 ng; lane 5, 400 ng). Lanes 1 and 6 represent 1 mg of immobilized histone free naked DNA used in an in vitro transcription reaction.
Lane 7 represents addition of wild-type Tat (36–72) (400 ng) and lane 8 represents the addition of mutant Tat (36–72) (400 ng) to the reaction.
Immobilized templates were then washed in transcription buffer and tested for transcription in vitro using HeLa nuclear extracts. Run-off of 32P-labeled
ranscripts (172 bases) was separated on a 6% urea/PAGE and exposed to a PhosphorImager cassette. Counts (cpm) from the RNA bands are shown
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321ENHANCEMENT OF p300 HAT ACTIVITY BY HIV-1 Tatcleavage efficiency of restriction endonucleases tar-
geted to the HIV-1 chromatin template, suggesting that
histone acetylation alone leads to nucleosome remodel-
ing (Steger et al., 1998; Li et al., 1999). Finally, in an
attempt to find other nonhistone transcription factors that
could serve as a substrate for Tat and p300 HAT com-
plex, we utilized all the known transcription factors af-
fecting HIV-1 transcription in vitro and have found that
the human TATA binding protein (TBP) can serve as a
substrate for acetylation in vitro (L. Deng and F. Kashan-
chi, unpublished results). The increased acetylation on
at the bottom. (C) The presence of intact nucleosomes in pre- and po
Following pull-down in transcription buffer, samples were prepared for
he original free histones used for the assembly reaction. Lanes 3 and 5
amples contained the addition of purified core histones prior to as
eactions, respectively. Samples from lanes 3–6 were finally washed tw
FIG. 5. Effect of wild-type and mutant Tat on HIV-1 proviral genome.
(50 ng) and CMV-p300 (6 mg) by the CaPO4 precipitation method. The p
7, and 10 after transfection. All experiments were performed twice in H
enhancement increases transcription on an HIV-1 nucleosomal DNA. A
of p300, which can acetylate Tat at positions 50 and 51. This complex m
on nucleosomal histone H4, which in turn enhances transcription of th1 M KCl buffer, incubated at 37°C for 4 h (to remove core histones from DNA
SDS/PAGE, and stained with Coomassie blue.TBP increased its DNA binding to the HIV-1 TATA box. It
remains to be seen whether TBP acetylation either alone
or in the context of SL1, TFIID, or TFIIIB could increase
the rate of cellular Pol I, II, and III transcription or simple
reinitiation of HIV-1- or TAR-independent promoters nor-
mally affected by Tat.
Unexpectedly, we also observed that Tat could auto-
acetylate itself, which was specific to the wild-type and
36–72 peptide but not the double-lysine mutant or 42–70
peptide, indicating that lysine residues 41 and 71 were
acceptor sites for autoacetylation. Peptide 42–70 could
cription reaction. Reactions were carried out at 53 for each sample.
transcription (see the last two parts in A). Lane 2 represents 1/10 of
s controls where DNA was not added to the original reaction; however,
. Lanes 4 and 5 represent samples from pre- and posttranscription
buffer D, plus 300 mM KCl and 0.1% NP-40, resuspended in 100 ml of
-1 cells were transfected either alone or with wild-type or mutant Tat
antigen ELISA was performed from supernatants obtained at days 3,
ells. (B) Proposed model of how Tat acetylation and p300 HAT activity
tylation of Tat at positions 41 and 71 allows for the efficient recruitment
w a change of conformation on p300 to increase its acetylation activity
1 promoter.sttrans
in vitro
serve a
sembly
ice in(A) HLM
24 gag
LM-1 c
utoace), TCA precipitated the supernatant, dried, denatured, run on a 4–20%
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322 DENG ET AL.not enhance the HAT activity of p300 to acetylate nucleo-
somal H4. Therefore, the presence of acetylated lysine
41 and 71 accounts for increased p300 HAT activity.
Lysine 41 mutation has been shown by us and others to
completely inactivate Tat function in vivo and it remains
to be seen whether lysine 71 also has similar importance
for Tat inactivation in vivo. It is important to note that in
our assays Tat autoacetylation was not 100% efficient.
We attribute the inefficiency of acetylation to various in
vitro preparations of Tat. For instance, Escherichia coli-
ade or machine-synthesized Tat, fractionated on a de-
atured HPLC column, lyophilized, and renatured prior to
se, is at best 2–10% active, as judged by activation of
he HIV-1 promoter in an in vitro transcription assays.
owever, we have recently observed a higher acetyla-
ion efficiency (30–40%) when Tat was made as a soluble
rotein produced from Baculovirus-infected cells (L.
eng, unpublished results). Future MALDI-TOF experi-
ents will determine whether autoacetylation requires
at dimers (absent in denatured preps) or other post-
ranslational modifications for optimal enzymatic activity.
It is important to note that our current study does not
dequately address whether Tat autoacetylation occurs
n vivo. However, we have performed a number of exper-
ments to address this issue and to this end have found
mbiguous and therefore unreportable results. For in-
tance, we find labeling of cells with any low or high beta
mitter, for the purpose of in vivo labeling of proteins, to
ause an artificial cell cycle blockage. This is true when
abels are added prior to or subsequent to transfection
xperiments. Specifically, low emitters block cells at
2/M and high emitters block cells at the G1/S phase of
he cell cycle. Therefore, in our view, results obtained
rom the in vivo labeling of Tat and its reported acetyla-
tion site at various positions in vivo are ambiguous. To
circumvent this problem, we have utilized Tat immuno-
precipitations in the presence of deacetylase inhibitors
from either transfected (HA tagged antibody) or infected
(polyclonal anti-Tat antibody) cells, followed by separa-
tion on SDS/PAGE, trypsin digestion, and acquisition of
peptide mass fingerprints, using MALDI-TOF. Again, we
find inconsistent results depending on which cell types
we use. For instance, K28, 41, and 50 are all acetylated at
early G1 (to varying degrees) in CEM and HL-60 cells, but
not in HeLa or U937 cells. However, we observe efficient
acetylation of K28, 41, 50, 51, and 71 in late G1/S in CEM
cells and efficient acetylation in HeLa and U937 cells in
G2 cells. To add to the complexity of in vivo acetylation
sites, in HIV-1-infected latent cells (ACH2, 8E5, U1, and
OM10.1) Tat shows variable levels of acetylation on K28
and 71 and no acetylation at some of the other reported
in vivo sites. Therefore, this level of compounding com-
plexity on in vivo acetylation sites requires further and
careful analysis with methods that truly score for in vivo
Tat acetylation sites. Future experiments utilizing elutri-
ated cell cycle fractions, and infection with various HIV-1clades in lymphocytes, will determine the exact sites of
Tat acetylation in vivo.
The effect of acetylation on transcription elongation
has also been demonstrated. Wittschieben et al. (1999)
showed that histone modification may be directly cou-
pled to transcription elongation by RNA polymerase II. In
vitro, purified RNA polymerase II could transcribe naked
DNA without substantial impediments, but its ability to
transcribe a chromatin template efficiently is severely
compromised. However, in vivo, the actively transcribing
complex contains not only RNA polymerase II, but also a
multisubunit complex, termed “elongator,” which associ-
ates with the hyperphosphorylated C-terminal domain of
the largest polymerase subunit (Otero et al., 1999), and
the piggybacking of chromatin modification activities by
helicases in general and RNA polymerase II in particular
is needed for transcription and other activities such as
mRNA capping, polyadenylation, and pre-mRNA splicing
(Otero et al., 1999). Therefore, in the case of HIV-1, it is
conceivable that cyclin T/cdk9 phosphorylation of RNA
Pol II CTD may aid in piggybacking of the Tat and HAT
complexes, which may in turn primarily acetylate his-
tones and play a significant role in transcriptional elon-
gation on repressed chromatin DNA.
Finally, it has been reported that the HAT activity of
CBP/p300 is stimulated by interaction with E1A or phos-
phorylation by cdk2/cyclin E complex (Ait-Si-Ali et al.,
1998). Along the same lines, we can envision a cdk9/
cyclin T complex that binds to substrates other than CTD
to modulate their activity. For instance, phosphorylation
of the CBP/p300 complex by cdk9/cyclin T could in-
crease its intrinsic HAT activity. Alternatively, cdk9/cyclin
T complex could phosphorylate histone tails, which may
serve as better substrates for HAT enzymes (L. Deng,
unpublished results). Future experiments will define
whether substrates other than CTD could contribute to
Tat’s multifunctional role in the HIV-1 life cycle.
MATERIALS AND METHODS
Antibodies
Antibodies were purchased from Upstate Biotechnol-
ogy (UBI): anti-acetyl histone H4, ChIPs grade, polyclonal
(Catalog No. 06-866); anti-acetyl-histone H4 (Lys 5), poly-
clonal (Catalog No. 06-866); anti-acetyl-histone H4 (Lys
8), (Catalog No. 06-0760); anti-acetyl-histone H4 (Lys 12),
(Catalog No. 06-761); and anti-acetyl-histone H4 (Lys 16),
(Catalog No. 06-762). Anti-acetyl histone H4, ChIP grade,
is a polyclonal antiserum from rabbit. It recognizes acety-
lated histone H4 and may cross-react with other acety-
lated proteins, such as H2B. All antibodies recognizing
histone H4-acetylated forms at positions 5, 8, 12, and 16
were IgG affinity-purified.
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323ENHANCEMENT OF p300 HAT ACTIVITY BY HIV-1 TatImmunoprecipitation
The nucleosomal arrays were assembled on pDH125
plasmid DNA with a histone:DNA ratio of 1:1.5 by dialysis.
The nucleosome histones were acetylated by p300 (HAT)
in the presence or in the absence of Tat. The acetylated
histones (14C-labeled) were immunoprecipitated by poly-
lonal anti-acetyl histone H4, ChIPs grade, anti-acetyl-
istone H4 (Lys 5), anti-acetyl-histone H4 (Lys 8), anti-
cetyl-histone H4 (Lys 12), and anti-acetyl-histone H4
Lys 16) antibodies. All antibodies were equalized on
DS/PAGE by staining for similar amounts of heavy and
ight chain prior to the IP reaction. Samples (IPs) were
llowed to rotate overnight at 4°C and the next day
rotein A1G beads (30% slurry, 100 ml) were added for
an additional 2 h. The IP beads were then washed with
TNE 150 buffer (150 mM NaCl; 100 mM Tris–HCl, pH 7.5,
1 mM EDTA, and 0.1% NP-40) at least four times. The
acetylated histones H4 (14C-labeled) were separated in a
4–20% SDS/PAGE (Invitrogen, Inc.), dried, and exposed to
a PhosphorImager cassette.
Peptide synthesis
The Tat peptides (36–72) were prepared on a PAL–
PEG–polystyrene resin by continuous-flow solid-phase
synthesis on a PerSeptive Biosystems Pioneer synthe-
sizer (Framingham, MA) using HBTU-activated Fmoc
amino acids. Side chain protection was as follows: Arg
(Pmc), Gln (Trt), Lys (Dde), and Ser and Tyr (But). Peptide
purification was achieved by conventional reverse-phase
HPLC on Vydac C18 (Hesperia, CA) in an overall yield of
25–30% based on starting resins. A similar approach was
used to synthesize the Tat (1–72) protein with an effi-
ciency of 2–3% yield for the wild-type and 1.5% yield for
the mutated protein. The purity of the peptides and pro-
teins was further confirmed by analytical reverse-phase
HPLC, capillary zone electrophoresis, and MALDI-TOF
mass spectrometry. The amounts of each peptide were
determined by Bio-Rad protein assay as well as by run-
ning small aliquots on 4–20% or 15% SDS/PAGE followed
by silver staining (Silver Stain Plus, Bio-Rad).
Biotinylated HIV-1 LTR DNA
The HIV-1 LTR DNA from 2147 to 1172 was amplified
by PCR from the pDH125 plasmid DNA (Dual T- and
M-tropic HIV-1 genome, the generous gift of D. Cho and
M. Martin, NIH/NIAID) with the biotinylated 59 primer,
iotin-59ACT TTTCCGGGGAGGCGCGATC39, and the 39
rimer, 59GCCACTGCTAGAGATTTCCACACTG39, oligo-
ucleotides providing every PCR product to contain a
iotin moiety at the 59 termini. The sequences of the
IV-1 LTR DNA were confirmed by the dideoxy sequenc-
ng method.ucleosome reconstitution by salt sequential dilution
Core histones were purified from HeLa cells by the
ethod of Simon and Felsenfeld (1979). The biotinylated
ononucleosomes were prepared by mixing the biotin-
lated HIV-1 LTR DNA and purified core histones by salt
equential dilution from 1 to 0.1 M NaCl (Imblazano, 1998;
tein and Mitchell, 1988). Ten to 20 mg of DNA of HIV-1
TR PCR products from plasmid pDH125 was mixed with
ml of 5 M NaCl, and 2 ml of 103 reconstitution buffer
(0.15 M Tris–HCl, pH 7.5; 1 mM DTT; 2 mM EDTA) by
pipetting up and down repeatedly. Next 30–40 mg of core
histones was added in a total volume of 50 ml adjusting
he volume by adding dd H2O. Samples were then gently
licked in the tube and incubated at 37°C for 20 min.
equential dilution was carried out by adding 10 ml of 13
reconstitution buffer every 10 min, for 3 h at 37°C. At
each time point, samples were mixed by gentle up and
down pipetting. An aliquot was run on agarose gel to
ensure proper assembly prior to each experiment.
Histone acetyltransferase assay
HAT assays were performed in a total of 30- to 60-ml
eactions at 37°C for 60 min in a buffer containing 1 ml of
urified GST–p300 HAT (1 mg/ml), 200–400 ng of sub-
trate proteins or peptides, and 1 mg of histones H2A,
H2B, H3, and H4 in 20 mM HEPES–NaOH, pH 7.4, 1 mM
dithiothreitol, 10 mM sodium butyric acid, and 1 ml of
14C]acetyl-Coenzyme A (65 mCi/mmol/ICN). Proteins
nd peptides were resolved on a 4–20% or 15% SDS/
AGE (Novex, Inc.). Gels were dried and exposed to a
hosphorImager cassette and bands were quantified
sing Molecular Dynamics software. Both HAT inhibitors,
ys-CoA and H3-CoA, were a generous gift from P. A.
ole (Johns Hopkins University).
Nase digestion of the nucleosomal and naked DNA
Aliquots of the assembled pDH125 chromatin DNA
100 ml, ;5 mgDNA) were added to 100 ml of prewarmed
37°C) digestion buffer (50 mM NaCl, 10 mM Tris–HCl,
H 7.4, 5 mM MgCl2, 1 mM CaCl2, 0.15% NP-40, and 25
nits of MNase, USB Catalog No. 70196Y) incubated for
5, 45, and 65 min at 37°C. The reactions were termi-
ated by the addition of 10 ml of 0.5 M EDTA and incu-
ated for an additional 15 min at 37°C. Following termi-
ation, the DNA was phenol/chloroform extracted, pre-
ipitated, and resuspended in 10 ml of TE buffer. As a
control, aliquots of naked plasmid pDH125 DNA were
also digested under the same conditions as described
above. The digested DNAs were precipitated, run on a
1% agarose gel, and stained with ethidium bromide.
In vitro transcription on chromatin templatesThe biotinylated DNA of HIV-1 LTR (from 2147 to
1172) was assembled with core histones into mononu-
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324 DENG ET AL.cleosomal chromatin. Biotinylated chromatin templates
were pulled down with streptavidin–agarose beads after
HAT assay with or without acetyl-CoA and Tat. The chro-
matin beads were washed with transcription buffer (20
mM HEPES (pH 7.9), 100 mM KCl, 12.5 mM MgCl2, 0.1
mM EDTA, 17% glycerol, and 1 mM dithiothreitol) twice
and preincubated at 30°C for 30 min, followed by the
addition of 3 ml [32P]UTP (Amersham Pharmacia Biotech,
400 Ci/mmol) and 20 ml HeLa nuclear cell extract (14
mg/ml), 3 ml of 20% PEG (6000), 3 ml of 50 mM MgCl2, 3
ml of 1 mM dithiothreitol, 1.5 ml of 50 mM ATP/CTP/GTP,
nd 18 ml of transcription buffer. 32P-labeled RNA prod-
cts were purified and separated on a 6% denaturing
crylamide urea gel (Invitrogen, Inc.).
ass spectrometry
The unacetylated or autoacetylated peptides were di-
ested with proline-specific endopeptidase (Seikagaku
orp.). The digested or undigested peptides were de-
alted using C18 ZipTips (Millipore) according to the man-
ufacturer’s procedure. A 1-ml aliquot of sample was
taken for peptide mass mapping on a PerSeptive Biosys-
tem DEPRO MALDI-TOF Mass Spectrometer using
a-cyano-4-hydroxycinnamic acid as the matrix. Analysis
was performed in the linear delayed-extraction mode,
with external calibration. The analysis of acetylation
mass was performed through the ProFound Web site lo-
cated at Rockefeller University (http://prowl.rockefeller.edu).
Transfection and HIV-1 detection of HLM-1 cells
HLM-1 cells (AIDS Research and Reference Reagent
Program, Catalog No. 2029) were derived from HeLa-
T41 cells integrated with one copy of HIV-1 genome
containing a Tat-defective mutation. The mutation was
introduced as a triple termination linker at the first AUG
of the Tat gene. HLM-1 cells are negative for virus par-
ticle production, but can be induced to express one cycle
of infectious HIV-1 particles after transfection with Tat
cDNA or mitogens such as TNF-a or sodium butyrate.
LM1 cells were grown in DMEM containing 10% FBS,
00 mg/ml of G418, plus 1% streptomycin, penicillin, and
% L-glutamine (Gibco BRL). Cells were grown to 75%
confluency prior to the transfection or passages.
HLM-1 cells were transfected with the plasmid DNAs
including Tat, mutant Tat lys41 (generous gift of D. Singer
at NIH/NCI), and p300 using the calcium phosphate
method. The transfected cells were washed after 4 h and
fresh complete DMEM with 10% fetal bovine was added
for the remainder of the experiment. The p24 gag antigen
was detected by using standard ELISA kit (Abbott) using
the supernatants of transfected cells at days 3, 7, and 10.
Protein transfectionLymphocyte (CEM (12D7)) cells were grown to the
mid-log phase of growth and processed for protein elec-troporation as described previously (Kashanchi et al.,
1992), with only minor modification, where cells were
electroporated at 230 V with HIV-1 LTR CAT DNA (3 mg)
long with Tat wild-type (1.0 mg) or mutant (KGLG dele-
ion) protein, and plated in 10 ml of complete RPMI 1640
edium for 18 h prior to harvest.
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